Van ECK Associates Corp Has $3.79 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Van ECK Associates Corp reduced its position in United Therapeutics Co. (NASDAQ:UTHR) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,756 shares of the biotechnology company’s stock after selling 138 shares during the period. Van ECK Associates Corp’s holdings in United Therapeutics were worth $3,792,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its holdings in shares of United Therapeutics by 176.2% during the 1st quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in United Therapeutics by 19.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after buying an additional 4,100 shares in the last quarter. Comerica Bank lifted its position in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after buying an additional 9,244 shares during the last quarter. Tri Locum Partners LP bought a new stake in shares of United Therapeutics during the 2nd quarter worth about $15,959,000. Finally, QRG Capital Management Inc. increased its holdings in shares of United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock valued at $4,880,000 after acquiring an additional 1,692 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Jefferies Financial Group boosted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. The Goldman Sachs Group raised their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of United Therapeutics stock in a transaction on Friday, November 1st. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $964,983.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 96,422 shares of company stock worth $35,251,428. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Up 1.8 %

United Therapeutics stock opened at $410.00 on Friday. The business has a 50 day moving average price of $359.20 and a two-hundred day moving average price of $322.77. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a market cap of $18.30 billion, a price-to-earnings ratio of 18.01, a price-to-earnings-growth ratio of 1.16 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period in the prior year, the company posted $5.38 earnings per share. United Therapeutics’s revenue was up 22.9% on a year-over-year basis. On average, analysts expect that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.